Device

Amulet (LAA Occluder) Overview

The Abbott Amplatzer Amulet is a dual-component lobe-and-disc LAA closure device — distal lobe anchors in the appendage neck, proximal disc seals the ostium against the LA wall. Covers design rationale, sizing, the simpler post-implant antithrombotic regimen, and Amulet-vs-WATCHMAN anatomical fit.

Common issues / troubleshooting

  • Disc not flush with the LA wall — indicates over-pulled or over-tensioned device; recapture and redeploy.
  • Lobe protrusion beyond the appendage neck — under-deployed lobe, risk of embolisation; recapture.
  • Peri-device leak around the disc — usually responds to upsizing or repositioning.
  • Device-related thrombus on the disc surface — surveillance imaging finding; reinstate anticoagulation.
  • Failed transseptal positioning into a chicken-wing LAA — Amulet still tolerates this better than single-piece devices.

The Amplatzer Amulet is Abbott’s left atrial appendage closure device. Unlike the WATCHMAN’s single-piece design, the Amulet uses two functional components — a distal lobe that anchors in the LAA neck and a proximal disc that seals the LAA ostium against the LA endocardium. The connecting waist allows independent adjustment of lobe and disc positioning.

How the system works

  • Self-expanding nitinol mesh structure with polyester fabric within both the lobe and the disc.
  • Delivered through a transseptal sheath; the lobe is deployed first into the appendage neck, then the disc is opened against the LA ostium.
  • The lobe’s stabilising wires engage the LAA wall; the disc lays flush against the LA face to seal the ostium externally.
  • Endothelialisation covers both surfaces over weeks to months.

Types / Variants

The current US device is the Amplatzer Amulet (Generation 2). Available in eight sizes covering LAA landing-zone diameters from 11 to 31 mm — broader range than WATCHMAN’s five sizes, giving better fit for marginal anatomies.

Design contrast vs WATCHMAN

FeatureAmuletWATCHMAN FLX
ArchitectureTwo-component lobe + discSingle-piece frame with PET face
Seal mechanismDisc seals at LA ostium externallyFrame face sits within LAA ostium
SizingEight sizes (11-31 mm)Five sizes (20-35 mm)
Depth requirementLower — disc handles ostial closure even with shallow lobe seatingHigher — entire device needs LAA depth
Post-implant regimenAspirin + clopidogrel then aspirin (no DOAC bridge for most)Short DAPT or DOAC bridge then aspirin
45-day TEEOptional in some protocolsStandard

Indications & candidate selection

Same overall indication as WATCHMAN: non-valvular AF with elevated stroke risk and a reason to discontinue long-term anticoagulation.

Amulet-favoured anatomies:

  • Shallow appendages where WATCHMAN’s depth requirement is borderline.
  • Chicken-wing morphology with a sharp early bend — the lobe seats in the proximal segment while the disc handles ostial closure.
  • Large or oval ostia where the disc’s separate sizing accommodates better.
  • Patients who cannot tolerate even a short DOAC bridge.

Key procedural considerations

Sizing

  • Pre-procedure imaging (TEE +/- cardiac CT) defines LAA neck (landing zone) diameter and ostium diameter.
  • Choose lobe size 2-6 mm larger than the LAA landing-zone diameter.
  • The disc auto-sizes off the lobe choice — disc is roughly 6-8 mm larger than the lobe.

Release criteria

  • Lobe fully expanded with stabilising wires engaged.
  • Lobe axis aligned with appendage neck axis.
  • Disc concave (slightly concave toward LA confirms tension is right; flat or convex suggests over-tension).
  • No disc protrusion into adjacent structures.
  • No peri-device leak >3 mm.

Trial context

The Amulet IDE trial randomised Amulet vs WATCHMAN 2.5 in non-valvular AF patients. Amulet was non-inferior on the primary efficacy endpoint (stroke, systemic embolism, cardiovascular death) and demonstrated more frequent immediate complete closure but with somewhat higher procedural complication rate. Real-world registries have refined the picture as operator experience has grown.

What to know in the lab

  • Transseptal puncture: inferior-posterior, same as WATCHMAN; the Amulet sheath is generally larger.
  • Engage the LAA with the delivery sheath stably before deploying the lobe — recapture is possible but each recapture risks anatomy disturbance.
  • Deploy the lobe first; assess position before releasing the disc.
  • Tug test the lobe before disc deployment.
  • Confirm disc concavity on TEE — flat or convex disc means too much tension, recapture and redeploy.

Post-implant management

  • Typical regimen: aspirin + clopidogrel for 1-6 months (institution-dependent), then aspirin alone long term.
  • DOAC bridge is not required for most patients — a major operational difference vs WATCHMAN.
  • Surveillance imaging at 45-90 days per institutional protocol; some centres image at 6 months instead of 45 days.

Common issues & troubleshooting

  • Disc not flush with LA wall — over-tensioned; recapture, advance lobe slightly deeper, redeploy disc.
  • Lobe protrusion — under-deployed lobe; recapture, advance further into appendage neck, redeploy.
  • Peri-device leak around the disc — upsize or reposition; persistent leak is uncommon given the dual-component seal.
  • Device-related thrombus on the disc — reinstate anticoagulation; reimage at 4-8 weeks.
  • Pericardial effusion — same risk profile as WATCHMAN; transseptal-related more than device-related.

Manufacturer reference

Watch

Short videos to help illustrate this topic. Embedded from the original channels — content belongs to them.

Video pending Add a youtube video ID to display: Amplatzer Amulet device walkthrough
Amplatzer Amulet device walkthrough · Abbott Structural Heart · Lobe-and-disc architecture and deployment sequence.
Video pending Add a youtube video ID to display: Amulet vs WATCHMAN anatomical considerations
Amulet vs WATCHMAN anatomical considerations · EP educational · Choosing the device that fits the appendage.

Last reviewed by Dr. Colombowala on May 22, 2026.

Not medical advice. This page is educational. Your situation may differ — discuss it with Dr. Colombowala or your treating physician before making decisions.